We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Insights Into Antibiotic Resistance

By Biotechdaily staff writers
Posted on 24 Aug 2005
Researchers working with large-scale computer simulations have discovered a tiny change in molecular structure that may account for drug resistance in Streptomices pneumoniae, the organism that causes childhood pneumonia and claims 3.5 million lives a year, mainly in developing countries.

Until now, no experiments have been conducted to find how changes at the molecular level are causing this resistance. More...
The new finding may be very useful in designing new drugs that are effective against the drug-resistant strain. It was discovered by Prof. Peter Coveny and co-workers from the University College London (UK) and Queen Mary, University of London (UK), using computer modeling techniques. The results of their work were published in the August 15, 2005, issue of a special theme issue of Philosophical Transactions of the Royal Society.

The researchers took experimental data gathered from other organisms to build computer models of the sites where drug molecules interact with an organism's protein molecules. Then they ran simulations and visualized what happens when a drug molecule approaches each site for both normal and drug-resistant strains of S pneumoniae. The simulations and visualizations exploited highly scalable parallel code, running on the UK's national supercomputing facilities.

Prof. Coveny and his colleagues could see that a very small but subtle difference in structure beween the normal and drug-resistant strains was to blame for the drug resistance. In the normal strain, a drug molecule binds tightly to the site, but in the drug-resistant strain, it approaches and then drifts slowly away. The researchers believe this finding may point the way to new drugs that can combat disease.





Related Links:
University College London >
Queen Mary, University of London

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.